Piflufolastat (18F), sold under the brand name Pylarify among others, is a radioactive diagnostic agent used for positron emission tomography (PET) imaging. [1][4][5] It is given by intravenous injection. [1][4] The most common adverse reactions include headache, altered taste, and fatigue. [4]

2021年5月27日 · The FDA approved the F 18-labeled prostate-specific membrane antigen (PSMA)–targeted positron emission tomography (PET) imaging agent 18F-DCFPyL (Pylarify) for use in prostate cancer, according to an announcement from the company responsible for the agent, Lantheus Holdings, Inc.

2020年12月9日 · PyL (also known as 18F-DCFPyL) is an investigational fluorinated PSMA-targeted PET imaging agent that enables visualization of localized prostate cancer as well as bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer.

FDA has approved Pylarify (piflufolastat F 18) – a drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer ...

Nearly all prostate cancers express prostate-specific membrane antigen (PSMA) and 18 F-DCFPyL (piflufolastat F 18) is a new FDA-approved positron emission tomography (PET) agent that targets PSMA for improved staging of prostate cancer.

PYLARIFY (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are …

2021年5月27日 · Instead of attaching the tracer molecule to “see” a cancer cell, you can attach a radioactive drug to kill the cancer. In Europe and Australia, and in international clinical trials, PSMA-targeting radionuclides, such as 177 Lu-PSMA-617 are being used to target and kill cancer in just those tiny outposts, leaving nearby cells undamaged.

2020年12月9日 · PyL™是一种针对前列腺癌的前列腺特异性膜抗原的正电子发射断层扫描（PET）成像剂。 2020年12月9日，开发、制造和商业化创新诊断和治疗药物及产品的企业Lantheus宣布美国食品药品监督管理局（FDA）已经接受了PyL™（18F-DCFPyL）的新药申请，并且批准了PyL NDA的优先审评，并指定处方药用户收费法的行动日期为2021年5月28日。 PyL™是一种针对前列腺癌的前列腺特异性膜抗原的正电子发射断层扫描（PET）成像剂。

PyL (also known as Fluorine-18-DCFPyL) is a clinical-stage, fluorinated PSMA-targeted imaging agent for the detection of prostate cancer. PSMA is the abbreviation for prostate-specific membrane antigen, a transmembrane protein that spans from the internal to the external surface of the membrane to which it is attached.

2021年5月27日 · PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy.